Tag: gist

Meet our CEO Mikael Maksimow  in the LSX World Congress in London on 29-30 April 2024!

We are excited to attend the ESMO Sarcoma and rare cancers Congress next week in Lugano. We are looking forward to learn the latest scientific advancements, connect with KOLs, engage with patient advocacy groups and network within the industry. Do not hesitate to reach out to our CEO, Mikael Maksimow, if you would like to […]

International rare disease day! Over 300 million people around the world are living with a rare disease! Then imagine how many of us are affected by rare diseases – whether as patients ourselves, caregivers, family members, or friends. While individually these conditions may affect only a small number of people, collectively they represent a significant portion […]

We are delighted to announce that Sartar Therapeutics received Orphan Drug Designation for GIST from the U.S. Food & Drug administration (FDA). This is a great addition to our Orphan Drug Designation in EU granted by the European Medicines Agency (EMA) earlier this year. See Orphan Drug Designation in FDA’s database.

Sartar participated the NOME Annual Meeting on 23rd Nov 2021 in Copenhagen, meeting mentors and other life science and medtech startups. NOME is an elite Nordic Mentoring Program that matches selected Nordic startups with highly skilled professionals to help them reach their goals and technology milestones. Sartar was selected to the program last June and has […]

We are proud to inform that the national innovation funding body Business Finland has granted R&D funding for Sartar Therapeutics. This R&D loan will allow us to advance the development of our product SAR001 towards clinical trials. We consider this positive decision as a significant credit for our technology for the treatment of soft tissue sarcomas.

Targeting phosphodiesterase 3A: discovery of a promising cancer therapy in Drug Target Review describes the science behind Sartar’s new cancer therapy, outlining emerging evidence that PDE3A protein-targeting compounds may induce sarcoma cell death by acting as a molecular glue between PDE3A and Schlafen 12 proteins. Link to original article